NCT00029822

Brief Summary

A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH.

  • Free study-related medical care provided.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,522

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started May 2001

Typical duration for phase_3

Geographic Reach
17 countries

54 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2001

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 23, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 24, 2002

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2005

Completed
Last Updated

June 9, 2008

Status Verified

June 1, 2008

First QC Date

January 23, 2002

Last Update Submit

June 6, 2008

Conditions

Keywords

Acute Urinary RetentionAURBenign Prostatic HyperplasiaBenign Prostatic HypertrophyBPHEnlarged Prostate

Outcome Measures

Primary Outcomes (1)

  • occurrence of first episode of acute urinary retention (AUR)

Secondary Outcomes (1)

  • need for benign prostatic hyperplasia (BPH)-related surgery, international prostate symptoms score (IPSS)

Interventions

Eligibility Criteria

Age55 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
* Has been suffering for at least 6 months with any of the following symptoms: * daytime or nighttime urinary frequency * urgent feeling to urinate * difficulty starting urinary stream * interruption of urinary stream * feeling of incomplete urination * Has not had a previous episode of acute urinary retention * Has not been diagnosed with prostate cancer * Has not had previous prostate surgery * Is not an insulin-dependent diabetic

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (54)

Medical Affiliated Research Center, Inc

Huntsville, Alabama, 35801, United States

Location

San Diego Urology Center

La Mesa, California, 91942, United States

Location

San Bernardino Urology Associates

San Bernardino, California, 92404, United States

Location

San Diego Urological Medical Group

San Diego, California, 92101, United States

Location

Pacific Clinical Research

Santa Monica, California, 90404, United States

Location

Urology Research Options

Aurora, Colorado, 80012, United States

Location

Connecticut Clinical Research Center

Waterbury, Connecticut, 06708-2652, United States

Location

South Florida Medical Research

Aventura, Florida, 33180, United States

Location

Tampa Bay Medical Research, Inc.

Clearwater, Florida, 34621, United States

Location

Advanced Research Institute

New Port Richey, Florida, 34652, United States

Location

Renstar Medical Research

Ocala, Florida, 34474, United States

Location

Renstar Medical Research

Plantation, Florida, 33324, United States

Location

Urology Associates

Marietta, Georgia, 30060, United States

Location

Northwestern Center for Clinical Research

Chicago, Illinois, 60611, United States

Location

Welborn Clinic

Evansville, Indiana, 47714, United States

Location

Northeast Indiana Research

Fort Wayne, Indiana, 46804-4128, United States

Location

Urology of Indiana, LLC

Indianapolis, Indiana, 46202, United States

Location

Maryland Prostate Cancer

Baltimore, Maryland, 21201, United States

Location

Maryland Urology Association

Towson, Maryland, 21204, United States

Location

Newton Wellesley Urology

Newton, Massachusetts, 02462, United States

Location

Lakeside Urology, P.C.

Saint Joseph, Michigan, 49085-2521, United States

Location

Se Urology Network

Southaven, Mississippi, 38671, United States

Location

Weill Cornell Medical Center

New York, New York, 10021, United States

Location

Advanced Clinical Trials

Eugene, Oregon, 97401, United States

Location

Albert Einstein Medical Center

Philadelphia, Pennsylvania, 19141, United States

Location

Center for Urologic Care

West Reading, Pennsylvania, 19611, United States

Location

Matrix Research

Greenville, South Carolina, 29650, United States

Location

Ut Medical Group, Inc.

Memphis, Tennessee, 38103-3446, United States

Location

Murfreesboro Medical Center

Murfreesboro, Tennessee, 37130, United States

Location

nTouch Research Corporation

Dallas, Texas, 75230, United States

Location

Urology Consultants, P.A.

San Antonio, Texas, 78229, United States

Location

Urology Associates

Fredericksburg, Virginia, 22401, United States

Location

Jeffrey Frankel

Seattle, Washington, 98166-3059, United States

Location

University of Wisconsin Hospital & Clinics

Madison, Wisconsin, 53792, United States

Location

Midwest Research Specialists, LLC

Milwaukee, Wisconsin, 53209, United States

Location

Sanofi-aventis Administrative Office

Macquarie Park, Australia

Location

Sanofi-aventis Administrative Office

Sofia, Bulgaria

Location

Sanofi-aventis Administrative Office

Laval, Canada

Location

Sanofi-aventis Administrative Office

Hørsholm, Denmark

Location

Sanofi-aventis Administrative Office

Helsinki, Finland

Location

Sanofi-aventis Administrative Office

Athens, Greece

Location

Sanofi-aventis Administrative Office

Budapest, Hungary

Location

Edith Wolfson Hospital

Holon, 58100, Israel

Location

Sapir Med. Center - Meir General Hospital

Kfar Saba, 44281, Israel

Location

Rabin Medical Center-Golda Campus

Petah Tikvah, 44281, Israel

Location

Sourasky Med. Center-Ichilov Hospital

Tel Aviv, 44281, Israel

Location

Sanofi-aventis Administrative Office

Gouda, Netherlands

Location

Sanofi-aventis Administrative Office

Lysaker, Norway

Location

Sanofi-aventis Administrative Office

Warsaw, Poland

Location

Sanofi-aventis Administrative Office

Porto Salvo, Portugal

Location

Sanofi-aventis Administrative Office

Bucharest, Romania

Location

Sanofi-aventis Administrative Office

Midrand, South Africa

Location

Sanofi-aventis Administrative Office

Barcelona, Spain

Location

Sanofi-aventis Administrative Office

Bromma, Sweden

Location

Related Publications (1)

  • Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int. 2006 Apr;97(4):734-41. doi: 10.1111/j.1464-410X.2006.06110.x.

Related Links

MeSH Terms

Conditions

Urinary RetentionProstatic Hyperplasia

Interventions

alfuzosin

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesProstatic DiseasesGenital Diseases, MaleGenital Diseases

Study Officials

  • ICD CSD

    Sanofi

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

January 23, 2002

First Posted

January 24, 2002

Study Start

May 1, 2001

Study Completion

March 1, 2005

Last Updated

June 9, 2008

Record last verified: 2008-06

Locations